NEUROHORMONES IN PATIENTS WITH ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION

被引:5
|
作者
POULEUR, H [1 ]
BENEDICT, CR [1 ]
ROUSSEAU, MF [1 ]
机构
[1] UNIV TEXAS, SCH MED, DEPT CARDIOL, HOUSTON, TX USA
关键词
NOREPINEPHRINE; ANGIOTENSIN-II; ACE INHIBITORS; NISOLDIPINE;
D O I
10.1007/BF00877315
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Measurements of plasma neurohormones in patients with left ventricular dysfunction are generally performed for research purpose rather than for diagnostic purpose or to guide therapy. These studies have shown that in patients with left ventricular dysfunction, several neurohormonal systems were activated, even in the absence of symptoms of congestive heart failure. This suggested that the cardiovascular system was not in a steady state and pointed out potential culprits for the progression of the disease. It has also been shown that the levels of several of these markers, particularly plasma norepinephrine, had an important prognostic value. Another value of neurohormonal studies obviously is the design of new therapeutic approaches aimed at improving symptoms and prognosis. In this respect, important therapeutic successes have been obtained with agents that interfere with the actions of some of these neurohormonal systems, such as with the use of the angiotensin-converting enzyme (ACE) inhibitors, particularly captopril and enalapril, and to a lesser extent, with beta-blockers. It can therefore be expected that, in the future, most patients with severe ischemic dysfunction will be treated with an ACE inhibitor. Nonetheless, neurohormonal control is not complete with these drugs; powerful vasoconstrictor forces, such as endothelin-1, remain activated, and an escape of angiotensin II from the control of ACE inhibition may exist. Thus, morbidity (e.g., progression towards congestive heart failure and angina pectoris) and mortality remain high despite treatment with ACE inhibitors. In the search for further improvements, the new generation of long-acting dihydropyridines is worth considering. Their afterload reducing action, coupled with powerful coronary vasodilation, might hypothetically delay the progression of ischemic LV dysfunction. In addition, the improved pharmacokinetic profile of these drugs avoiding wide peak and trough variations in plasma levels may avoid triggering some neurohormonal reflexes.
引用
收藏
页码:313 / 317
页数:5
相关论文
共 50 条
  • [31] LEFT-VENTRICULAR EJECTION FRACTION RESPONSE TO AMRINONE BOLUS - A CHALLENGE IN ORDER TO IDENTIFYING PATIENTS WITH ISCHEMIC CARDIOMYOPATHY AND REVERSIBLE CHRONIC LEFT-VENTRICULAR DYSFUNCTION
    BALINO, NAP
    RODRIGUEZ, OMA
    ITURRIA, M
    MERETTA, A
    CRAGNOLINO, D
    PERRONE, S
    MELE, E
    PALACIOS, I
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, : A343 - A343
  • [32] RELATION BETWEEN LEFT-VENTRICULAR SHAPE AND DOPPLER FILLING PARAMETERS IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION
    TISCHLER, MD
    LEWINTER, MM
    CIRCULATION, 1994, 90 (04) : 603 - 603
  • [33] LEFT-VENTRICULAR DYSFUNCTION IN PATIENTS WITH VENTRICULAR SEPTAL-DEFECT
    ALTIERI, PI
    COX, RA
    MEDINA, A
    VALLE, LD
    TORRES, M
    GUERRA, E
    CLINICAL RESEARCH, 1977, 25 (03): : A203 - A203
  • [34] VALUE OF ECHOGRAPHICALLY DETERMINED LEFT-VENTRICULAR CONTRACTILITY PARAMETERS IN PATIENTS WITH AND WITHOUT LEFT-VENTRICULAR DYSFUNCTION
    SCHINZ, A
    ZEITSCHRIFT FUR KARDIOLOGIE, 1977, 66 (09): : 530 - 530
  • [35] RELATION BETWEEN LEFT-VENTRICULAR DIASTOLIC FUNCTION AND EXERCISE TOLERANCE IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION
    HEO, J
    ISKANDRIAN, AS
    HAKKI, AH
    CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1986, 12 (05): : 311 - 316
  • [36] TOLERABILITY OF ENALAPRIL INITIATION BY PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION - RESULTS OF THE MEDICATION CHALLENGE PHASE OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION
    KOSTIS, JB
    SHELTON, BJ
    YUSUF, S
    WEISS, MB
    CAPONE, RJ
    PEPINE, CJ
    GOSSELIN, G
    DELAHAYE, F
    PROBSTFIELD, JL
    CAHILL, L
    DUTTON, D
    AMERICAN HEART JOURNAL, 1994, 128 (02) : 358 - 364
  • [37] PRESERVATION OF LEFT-VENTRICULAR PERFORMANCE WITH REDUCED ISCHEMIC DYSFUNCTION BY INTRAVENOUS NISOLDIPINE
    KIMBALL, BP
    WATSON, KR
    BUI, S
    FRANKEL, D
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (04): : 400 - 405
  • [38] EVALUATION OF LEFT-VENTRICULAR DYSFUNCTION AND THE PROGNOSIS OF ISCHEMIC DISEASE BY RADIONUCLIDE ANGIOGRAPHY
    CASSAGNES, J
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1993, 86 : 39 - 43
  • [39] CARDIOKYMOGRAPHY - QUANTITATIVE-ANALYSIS OF REGIONAL ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION
    DIAMOND, GA
    CHAG, M
    VAS, R
    FORRESTER, JS
    AMERICAN JOURNAL OF CARDIOLOGY, 1978, 41 (07): : 1249 - 1257
  • [40] HEMODYNAMIC COMPARISON OF DOPEXAMINE HYDROCHLORIDE AND DOPAMINE IN ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION
    JACKSON, NC
    TAYLOR, SH
    FRAIS, MA
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (05): : C73 - C77